{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:49:26Z","timestamp":1793317766310,"version":"4.5.0"},"reference-count":81,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The incidence of thromboembolic events (TEs) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) has rarely been reported. The MEDLINE, EMBASE, and the Cochrane Library databases were searched. The primary outcome was the incidence of TEs, and the secondary outcome was the relationship between TEs and overall survival (OS) following ICI therapy. A subgroup analysis of TE incidents was performed according to the TE type and combination regimens. The I2 statistic was used to determine the heterogeneity, and funnel plots and Egger\u2019s test were used to assess publication bias. A total of 16,602 patients with NSCLC in 63 experimental arms were included in the analysis. The rate of TEs ranged from 0.1% to 13.8%, and the pooled overall incidence of all-grade TEs was 3% (95% confidence interval [CI], 2%\u20134%). The pooled rate of high-grade TEs was 1% (95% CI, 1%\u20132%). The venous and arterial TE rates were 3% (95% CI, 2%\u20134%) and 1% (95% CI, 1%\u20132%), respectively. Patients who received immunotherapy + chemoradiotherapy had the highest incidence of TEs (7%). The TE pooled rate was higher in patients treated with combined ICIs than in those treated with mono ICIs (4% vs. 2%). The OS was lower in patients with TEs than in those without TEs (hazard ratio, 1.4; 95% CI, 1.02%\u20131.92%). The incidence of TEs in NSCLC patients treated with ICIs was reasonable. Nonetheless, clinicians must be aware of potential thrombotic complications and treat them promptly.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_1031_23","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T17:00:18Z","timestamp":1714496418000},"page":"509-521","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Incidence of thromboembolic events in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis"],"prefix":"10.4103","volume":"20","author":[{"given":"Miaomiao","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Oncology, Yantai Yuhuangding Hospital, Affiliated with Medical College of Qingdao University, Yantai, Shandong, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yantai Yuhuangding Hospital, Affiliated with Medical College of Qingdao University, Yantai, Shandong, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yantai Yuhuangding Hospital, Affiliated with Medical College of Qingdao University, Yantai, Shandong, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yantai Yuhuangding Hospital, Affiliated with Medical College of Qingdao University, Yantai, Shandong, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"New Engl J Med"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor):Dose-expansion cohort of a multicentre, open-label, phase 1b trial","volume":"18","author":"Gulley","year":"2017","journal-title":"Lancet Oncol"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):A randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New Engl J Med"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.4103\/jcrt.jcrt_721_21","article-title":"First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer:A classical and network meta-analysis","volume":"19","author":"Mutlu","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4103\/jcrt.jcrt_723_23","article-title":"Immunotherapy for early-stage non-small cell lung cancer:A system review","volume":"19","author":"Gao","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4103\/jcrt.jcrt_855_21","article-title":"Effectiveness and safety of camrelizumab combined with chemotherapy in nonsquamous nonsmall cell lung cancer as the second-line therapy:A retrospective analysis","volume":"18","author":"Huang","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s10637-019-00881-6","article-title":"Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors","volume":"38","author":"Ando","year":"2020","journal-title":"Invest New Drug"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.thromres.2011.10.025","article-title":"Anticancer treatment and thrombosis","volume":"129","author":"Falanga","year":"2012","journal-title":"Thromb Res"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases:Early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.20.03579","article-title":"Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score\u226550%:Randomized, double-blind phase III KEYNOTE-598 study","volume":"39","author":"Boyer","year":"2021","journal-title":"J Clin Oncol"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/ijc.33399","article-title":"Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer:KEYNOTE-042 China study","volume":"148","author":"Wu","year":"2021","journal-title":"Int J Cancer"},{"key":"R14-20241021","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtho.2020.10.004","article-title":"Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"8406","DOI":"10.1002\/cam4.3456","article-title":"Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer","volume":"9","author":"Tfayli","year":"2020","journal-title":"Cancer Med"},{"key":"R16-20241021","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejca.2020.06.007","article-title":"Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric\/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma:An open-label, phase Ia\/b study (JVDJ)","volume":"137","author":"Bang","year":"2020","journal-title":"Eur J Cancer"},{"key":"R17-20241021","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik","year":"2021","journal-title":"Blood"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/cancers12010067","article-title":"Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients","volume":"12","author":"Nichetti","year":"2019","journal-title":"Cancers"},{"key":"R19-20241021","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s12094-020-02515-3","article-title":"Incidence of venous thromboembolic events in cancer patients receiving immunotherapy:A single-institution experience","volume":"23","author":"Gutierrez-Sainz","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"R20-20241021","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1007\/s00520-021-06139-3","article-title":"Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy","volume":"29","author":"Guven","year":"2021","journal-title":"Support Care Cancer"},{"key":"R21-20241021","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2021.06.018","article-title":"Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer:A retrospective multicentric cohort study","volume":"205","author":"Deschenes-Simard","year":"2021","journal-title":"Thromb Res"},{"key":"R22-20241021","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.medj.2021.02.002","article-title":"Increased incidence of venous thromboembolism with cancer immunotherapy","volume":"2","author":"Roopkumar","year":"2021","journal-title":"Med"},{"key":"R23-20241021","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"New Engl J Med"},{"key":"R24-20241021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012):Results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"R25-20241021","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jtho.2018.02.022","article-title":"Phase 1\/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation\u2014positive advanced non-small cell lung cancer (CheckMate 370)","volume":"13","author":"Spigel","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R26-20241021","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1158\/1078-0432.CCR-19-1305","article-title":"Phase I\/Ib study of pembrolizumab plus vorinostat in advanced\/metastatic non-small cell lung cancer","volume":"25","author":"Gray","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R27-20241021","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000500571","article-title":"A phase 1b\/2 study of the Bruton tyrosine kinase inhibitor ibrutinib and the PD-L1 inhibitor durvalumab in patients with pretreated solid tumors","volume":"97","author":"Hong","year":"2019","journal-title":"Oncology"},{"key":"R28-20241021","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2020.02.003","article-title":"Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer","volume":"142","author":"Besse","year":"2020","journal-title":"Lung Cancer"},{"key":"R29-20241021","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer:Results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J Clin Oncol"},{"key":"R30-20241021","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer:A randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"R31-20241021","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"New Engl J Med"},{"key":"R32-20241021","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"New Engl J Med"},{"key":"R33-20241021","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2019.06.021","article-title":"Acute vascular events as a possibly related adverse event of immunotherapy:A single-institute retrospective study","volume":"120","author":"Bar","year":"2019","journal-title":"Eur J Cancer"},{"key":"R34-20241021","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL):A randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R35-20241021","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","article-title":"First-line nivolumab plus ipilimumab in advanced NSCLC:4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R36-20241021","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.17476","article-title":"Thromboembolic risk in patients with lung cancer receiving systemic therapy","volume":"194","author":"Madison","year":"2021","journal-title":"Brit J Haematol"},{"key":"R37-20241021","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.thromres.2021.10.014","article-title":"Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy","volume":"208","author":"Hill","year":"2021","journal-title":"Thromb Res"},{"key":"R38-20241021","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1111\/cas.14980","article-title":"Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer:KEYNOTE-189 Japan Study","volume":"112","author":"Horinouchi","year":"2021","journal-title":"Cancer Sci"},{"key":"R39-20241021","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.21.00276","article-title":"SAKK 16\/14:Durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small-cell lung cancer\u2014a multicenter single-arm phase II trial","volume":"39","author":"Rothschild","year":"2021","journal-title":"J Clin Oncol"},{"key":"R40-20241021","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(19)30458-9","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF):A multicohort, non-randomised, open-label, phase 1a\/b trial","volume":"20","author":"Herbst","year":"2019","journal-title":"Lancet Oncol"},{"key":"R41-20241021","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC","volume":"16","author":"Chu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R42-20241021","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"New Engl J Med"},{"key":"R43-20241021","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.lungcan.2021.07.004","article-title":"Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure","volume":"159","author":"Lam","year":"2021","journal-title":"Lung Cancer"},{"key":"R44-20241021","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","article-title":"A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study","volume":"17","author":"Bestvina","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R45-20241021","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer:A single-centre, randomised phase 2 trial","volume":"22","author":"Altorki","year":"2021","journal-title":"Lancet Oncol"},{"key":"R46-20241021","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2019.05.001","article-title":"Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer\u2014The ETOP NICOLAS trial","volume":"133","author":"Peters","year":"2019","journal-title":"Lung Cancer"},{"key":"R47-20241021","doi-asserted-by":"crossref","first-page":"1959979","DOI":"10.1080\/2162402X.2021.1959979","article-title":"Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer","volume":"10","author":"Landman","year":"2021","journal-title":"Oncoimmunology"},{"key":"R48-20241021","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s12094-020-02515-3","article-title":"Incidence of venous thromboembolic events in cancer patients receiving immunotherapy:A single-institution experience","volume":"23","author":"Gutierrez-Sainz","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"R49-20241021","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"New Engl J Med"},{"key":"R50-20241021","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):A phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"R51-20241021","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","article-title":"FDA approval summary:Pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1","volume":"21","author":"Sul","year":"2016","journal-title":"Oncologist"},{"key":"R52-20241021","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"New Engl J Med"},{"key":"R53-20241021","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/annonc\/mdx008","article-title":"Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer:A phase 1 trial","volume":"28","author":"Hui","year":"2017","journal-title":"Ann Oncol"},{"key":"R54-20241021","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.lungcan.2018.05.023","article-title":"Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy","volume":"122","author":"Lee","year":"2018","journal-title":"Lung Cancer"},{"key":"R55-20241021","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC):An open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"R56-20241021","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jtcvs.2018.11.124","article-title":"Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer","volume":"158","author":"Bott","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R57-20241021","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/j.cllc.2018.01.001","article-title":"Real-world efficacy and safety of nivolumab for advanced non-small-cell lung cancer:A retrospective multicenter analysis","volume":"19","author":"Kobayashi","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"R58-20241021","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042):A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"R59-20241021","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/jcm8060762","article-title":"Disorder of coagulation-fibrinolysis system:An emerging toxicity of anti-PD-1\/PD-L1 monoclonal antibodies","volume":"8","author":"Sato","year":"2019","journal-title":"J Clin Med"},{"key":"R60-20241021","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%:A multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"R61-20241021","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2021.02.034","article-title":"Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC):Data from the Phase 1 NSCLC expansion cohort","volume":"155","author":"Moreno","year":"2021","journal-title":"Lung Cancer"},{"key":"R62-20241021","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/jth.15272","article-title":"Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors","volume":"19","author":"Icht","year":"2021","journal-title":"J Thromb Haemost"},{"key":"R63-20241021","doi-asserted-by":"crossref","first-page":"e000108","DOI":"10.1136\/esmoopen-2016-000108","article-title":"Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer","volume":"2","author":"Nishio","year":"2017","journal-title":"ESMO Open"},{"key":"R64-20241021","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"New Engl J Med"},{"key":"R65-20241021","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.19.02446","article-title":"Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study","volume":"38","author":"Herbst","year":"2020","journal-title":"J Clin Oncol"},{"key":"R66-20241021","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer:A non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol"},{"key":"R67-20241021","doi-asserted-by":"crossref","first-page":"103782","DOI":"10.1016\/j.critrevonc.2022.103782","article-title":"Venous thromboembolism in cancer and cancer immunotherapy","volume":"178","author":"Kacimi","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"R68-20241021","doi-asserted-by":"crossref","first-page":"101535","DOI":"10.1016\/j.eclinm.2022.101535","article-title":"Toxicity spectrum of immunotherapy in advanced lung cancer:A safety analysis from clinical trials and a pharmacovigilance system","volume":"50","author":"Yan","year":"2022","journal-title":"Eclinicalmedicine"},{"key":"R69-20241021","first-page":"101","article-title":"High incidence of venous thromboembolism due to immune checkpoint inhibitors:An immunotherapy-related toxicity","volume":"6","author":"Li","year":"2021","journal-title":"J Nutr Oncol"},{"key":"R70-20241021","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4103\/jcrt.JCRT_1088_20","article-title":"Increased psychomotor retardation and tension as short-term neuropsychiatric adverse events of immune checkpoint inhibitors:A prospective cohort study","volume":"18","author":"Khalil","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"R71-20241021","doi-asserted-by":"crossref","first-page":"e10772","DOI":"10.1097\/MD.0000000000010772","article-title":"Pembrolizumab-induced acute thrombosis:A case report","volume":"97","author":"Kunimasa","year":"2018","journal-title":"Medicine"},{"key":"R72-20241021","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nature17412","article-title":"Potentiating the antitumour response of CD8+T cells by modulating cholesterol metabolism","volume":"531","author":"Yang","year":"2016","journal-title":"Nature"},{"key":"R73-20241021","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R74-20241021","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer:A meta-analysis","volume":"6","author":"Hu","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"R75-20241021","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jfma.2019.07.025","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients:A review when cardiology meets immuno-oncology","volume":"119","author":"Chen","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"R76-20241021","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1378\/chest.12-1446","article-title":"Use of oral glucocorticoids and the risk of pulmonary embolism:A population-based case-control study","volume":"143","author":"Stuijver","year":"2013","journal-title":"Chest"},{"key":"R77-20241021","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"New Engl J Med"},{"key":"R78-20241021","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"New Engl J Med"},{"key":"R79-20241021","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4103\/jcrt.JCRT_967_20","article-title":"Determination of the factors contributing to depression and anxiety in advanced stage lung cancer patients","volume":"19","author":"Ozdilekcan","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"R80-20241021","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.4103\/jcrt.JCRT_241_19","article-title":"Efficacy and safety of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy in HER2-negative breast cancer","volume":"15","author":"Yang","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"R81-20241021","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41591-020-0964-7","article-title":"Myocardial infarction accelerates breast cancer via innate immune reprogramming","volume":"26","author":"Koelwyn","year":"2020","journal-title":"Nat Med"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1031_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:39:06Z","timestamp":1787067546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1031_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1031_23","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"2023-05-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}